

NEWS, VIEWS, & REVIEWS

Practical Approaches to the Diagnosis and Management of Sensitive Skin: A Scoping Review

Erika T. McCormick BSc, Sapana Desai MD, Adam Friedman MD FAAD

George Washington University Medical Faculty Associates, Department of Dermatology,

George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Introduction

Sensitive skin (SS), a subjective syndrome of cutaneous hyperreactivity to otherwise innocuous stimuli, affects approximately 40-50% of the population. Increased stratum corneum permeability, hyperactivity of intraepidermal nerve fibers, and sensitization of transient receptor potential vanilloid 1 (TRPV1) channels contribute to the lower sensitivity threshold and neurosensory discomfort of SS, however, pathophysiology is incompletely understood.^{1,2} SS manifests as dry, easily irritated skin (commonly on the face) with reactive erythema, pruritis, burning, tightness, or stinging. There is limited data on SS management to guide clinical decision-making and no consensus on best approach. Despite these challenges, dermatologists should be equipped to encounter SS; individuals with SS are more likely seek dermatology care and more likely to rely on medical advice for skincare product purchases than those without SS.³ Herein, we present a practical approach to the patient with SS and briefly highlight novel treatments using current evidence in the literature.

SS should be considered a diagnosis of exclusion; other dermatoses that increase skin sensitivity (Table 1) must be identified and appropriately treated if present. Patients initially presenting with SS should discontinue all topical products for two weeks, then undergo dermatologic evaluation. If SS is still suspected, products can be gradually tested and reintroduced with emphasis on identifying triggers for reactivity. SS may be triggered by lifestyle-related (cosmetics, products, foods, alcohol), environmental (pollution, UV exposure, heat, weather), or endogenous (psychological factors, hormonal changes, stress) factors.¹ Patients should develop a list of triggers and

minimize exposures.^{4,5} Sensitive Scale-10 (SS-10), a validated scale measuring severity of SS,⁶ can be used to establish a baseline and track symptoms longitudinally.

During acute periods of SS reactivity, severe neurosensory discomfort can be managed with topical calcineurin inhibitors (TCIs). TCIs' anti-inflammatory and anti-pruritic effects occur through inhibition of calcineurin-dependent T-cell activation, reducing pro-inflammatory cytokines. Calcineurin inhibition also paradoxically favors activation of TRPV1, a channel perpetuating neurogenic inflammation.⁷ This explains the initial irritating effect of TCI application, while eventual channel desensitization allows for soothing effects of prolonged use.⁸ SS, associated with TRPV1 sensitization, benefits from this long-term mechanism; application of pimecrolimus 1% cream significantly reduces pruritis and burning sensations in SS patients.⁹

Long-term management of SS necessitates daily skincare that improves skin hydration, increases stratum corneum integrity, and decreases susceptibility to irritants.¹⁰⁻¹² Fundamental SS skincare routines include mild cleanser, moisturizer, and sun protection.¹³ Preferred cleansers have a pH near physiological skin and contain emollients. Patients should avoid facial washing with water or soap to limit excessive removal of lipids and natural moisturizing factors.¹⁴ Optimal moisturizers contain humectants (eg: glycerin, hyaluronic acid, aloe vera) and emollients (ceramides, plant oils).¹ Lastly, daily sunscreen should be broad-spectrum, SPF 30 or greater, and include inorganic UV filters (titanium dioxide, zinc oxide) due to lower allergenic potential.¹¹ All formulations should be fragrance-free, hypoallergenic, and non-irritating.

Active ingredients in skincare products can be tailored to target symptoms of SS. There is currently no federal or legal standard regulating ingredients in products marketed for SS,¹⁵ and many lack testing in SS specifically. Therefore, understanding of the specific active ingredients in sensitive skincare and their utility in related conditions can aid product counseling. We review the evidence for common active ingredients in SS products in Table 2. The best products will likely involve a synergistic effect of several ingredients.

Table 1. Differential Diagnosis for Sensitive Skin

Differential Diagnosis for Sensitive Skin
Eczema/Atopic Dermatitis
Rosacea
Seborrheic Dermatitis
Irritant or Allergic Contact Dermatitis
Photodermatoses
Urticaria
Acne
Xerosis

Table 1. Current Evidence on Common Active Ingredients Found in Sensitive Skin (SS) Products.

Active Ingredient	Purpose	Mechanism	Relevant Evidence	Potential Utility in SS
Niacinamide ²² <i>aka nicotinamide</i>	Involved in energy production as component of coenzymes NAD and NADP, which serve as antioxidants in their reduced forms (NADH/ NADPH)	Decreases pro-inflammatory NF- κ B signaling by inhibiting PARP- 1 Reduces pruritis by inhibiting cAMP-phosphodiesterase, which is involved in mast cell histamine release	Increases synthesis of ceramides, free fatty acids, and cholesterol <i>in vitro</i> Topical application reduced TEWL in a clinical study (n=12)	Topical application may improve barrier function
Peptides	Acetyl dipeptide- 1 cetyl ester ²²	Promotes pro-opiomelanocortin gene expression, which stimulates release of opioid metenkephalin and reduces CGRP release (which otherwise activates TRPV1)	Reduced PGE2 secretion and NF- κ B signaling <i>in vitro</i> Upregulated Aquaporin 2, Filaggrin genes <i>in vitro</i> (promote epidermal barrier) 2 clinical studies from manufacturer brochures report increased skin comfort and decreased heat sensations after use	Expected to help mitigate unpleasant sensations associated with hyperactivity of cutaneous nerve fibers
	Panthenol/ Pantothenic Acid ²²	CoA is essential for metabolic processes including synthesis of epidermal intercellular lipids	Moisturized and improved skin barrier in RCT of AD patients Promotes wound healing in multiple clinical studies, thought to be due to fibroblast activation	Expected to improve skin barrier
	Palmitoyl tripeptide- 8 ²²	Downstream effects of include reduction of NF- κ B signaling and reduced inflammatory response	Demonstrated improvement in erythema, dryness, edema, and stinging in a clinical study of rosacea patients	Symptom reduction in rosacea should translate to SS given symptom overlap
	Ceramides ^{10,14,23–25}	Essential role in providing and maintaining barrier function of epidermis	Ceramides are relatively decreased in the stratum corneum of SS patients Lipidome analysis in SS demonstrated decreased levels of ceramides More effective than standard emollients for improving skin hydration and inflammation in AD	Essential for barrier function Demonstrated lack of ceramides in SS

Other ingredients reported in literature to have potential utility in SS include glycyrrhetic acid (and derivatives),^{22,26} 4- t- butylcyclohexanol^{22,27–29} allantoin,²² *Laminaria ochroleuca*,²² *Centella Asiatica* (Gotu kola),²² bakuchiol,³⁰ *Bifidobacterium longum* extract,³¹ coriander³² and flax seed oil³³ supplementation, *R. rosea* extract,³⁴ Grifolin derivatives (*Albatrellus ovinus*),³⁵ neurosensine³⁶

TEWL= transepidermal water loss, AD = atopic dermatitis

Beyond the above approaches, phototherapy has been investigated in SS given demonstrated anti-inflammatory effects in other conditions.^{16,17} In one study, red light emitting diode (LED) exposure twice weekly allowed 77% of participants (n=30) to achieve significant SS-10 score reduction within 6 or fewer sessions.¹⁷ Interestingly, SS-10 scores remained decreased at 2 month follow-up from the final session, suggesting benefits may persist beyond the final treatment.¹⁷ Other studies demonstrated successful SS symptom reduction using low-level light therapy,¹⁸ intense pulsed light (IPL) alone¹⁶, and in IPL combination with shortwave radiofrequency.¹⁹ Phototherapy shows promise as an intensive SS therapy, but additional evidence is needed to determine the most advantageous regimen.

Novel approaches to SS include extracellular vesicles extracted from mesenchymal stem/stromal cells, which were tested in 22 SS patients. This therapy (1mL application BID for 28 days) improved objective and subjective SS symptoms and reduced reactions to chemical irritation.²⁰ Plasma rich in growth factors (PGRF) was studied in 5 SS patients; personalized PGRF serums were prepared from peripheral blood and applied to the face twice daily for 3 months. Results included increased skin hydration and decreased objective symptoms of SS.²¹ Although there were no adverse effects reported in these studies, they are likely not feasible for widespread use.

In conclusion, SS management is highly personalized and relies on strong patient-physician partnership and a high level of patient involvement to achieve relief of symptoms, optimize skincare, and identify triggers. There is a need for affordable, efficacious, and scientifically-tested therapeutics for SS. Currently, an overall paucity of literature on SS management and heterogenous methods for diagnosis and outcome-tracking make it difficult to gauge comparative efficacy of therapeutic options. We intended to simplify current evidence and highlight relevant data applicable to clinical practice. We hope that future research can explore SS pathophysiology, therapeutic targets, and product evaluation in SS patients.

Acknowledgement

EM's research is funded through an independent research grant from Galderma.

Disclosure

AF and EM have received research grants from Galderma.

References

- Guerra-Tapia A, Serra-Baldrich E, Prieto Cabezas L, et al. Diagnosis and treatment of sensitive skin syndrome: An algorithm for clinical practice. *Actas Dermosifiliogr*. 2019;110(10):800-808. doi:10.1016/J.AD.2018.10.021
- Resende DISP, Ferreira MS, Sousa-Lobo JM, et al. Usage of synthetic peptides in cosmetics for sensitive skin. *Pharmaceuticals (Basel)*. 2021;14(8). doi:10.3390/PH14080702
- Misery L, Sibaud V, Merial-Kieny C, et al. Sensitive skin in the American population: Prevalence, clinical data, and role of the dermatologist. *Int J Dermatol*. 2011;50(8):961-967. doi:10.1111/J.1365-4632.2011.04884.X
- Lev-Tov H, Maibach HI. The sensitive skin syndrome. *Indian J Dermatol*. 2012;57(6):419. doi:10.4103/0019-5154.103059
- Inamadar AC, Palit A. Sensitive skin: An overview. *Indian J Dermatol Venereol Leprol*. 2013;79(1):9-16. doi:10.4103/0378-6323.104664
- Misery L, Jean-Decoster C, Mery S, et al. A new ten-item questionnaire for assessing sensitive skin: The sensitive scale-10. *Acta Derm Venereol*. 2014;94(6):635-639. doi:10.2340/00015555-1870/
- Planells-Cases R, Garcia-Sanz N, Morenilla-Palao C, et al. Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia. *Pflugers Arch*. 2005;451(1):151-159. doi:10.1007/S00424-005-1423-5
- Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin. *Br J Dermatol*. 2010;163(1):70-77. doi:10.1111/J.1365-2133.2010.09757.X
- Xie ZQ, Lan YZ. Effectiveness of pimecrolimus cream for women patients with sensitive skin and its underlying mechanism. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao*. 2012;34(4):375-378. doi:10.3881/J.ISSN.1000-503X.2012.04.012
- Cheong WK. Gentle cleansing and moisturizing for patients with atopic dermatitis and sensitive skin. *Am J Clin Dermatol*. 2009;10 Suppl 1:13-17. doi:10.2165/0128071-200910001-00003
- Goh CL, Wu Y, Welsh B, et al. Expert consensus on holistic skin care routine: Focus on acne, rosacea, atopic dermatitis, and sensitive skin syndrome. *J Cosmet Dermatol*. Epub ahead of print; Nov 21, 2022. doi:10.1111/JOC.D.15519
- Hawkins SS, Subramanyan K, Liu D, et al. Cleansing, moisturizing, and sun-protection regimens for normal skin, self-perceived sensitive skin, and dermatologist-assessed sensitive skin. *Dermatol Ther*. 2004;17:63-68. doi:10.1111/J.1396-0296.2004.04S1008.X
- Hawkins SS, Foy V. The spectrum of sensitive skin: considerations for skin care in vulnerable populations. *J Drugs Dermatol*. 2019;18(1s):s68-74. PMID: 30681812
- Schachner LA, Andriessen A, Benjamin L, et al. A consensus about the importance of ceramide containing skincare for normal and sensitive skin conditions in neonates and infants. *J Drugs Dermatol*. 2020;19(8):769-776. doi:10.36849/JDD.2020.5252
- Tantry E, Perez-Sanchez A, Fu S, et al. Labeling laws for personal care products: Potential pitfalls for the consumer. *Skin Therapy Lett*. 2021;26(5):1-6.
- Yuan J, Gao Y, Li Z, et al. Effective of a novel technique for sensitive skin treatment with optimal pulse technology: A clinical study. *J Cosmet Dermatol*. 2022;21(10):4345-4353. doi:10.1111/JOC.D.14764
- Sonbol H, Brenaut E, Nowak E, et al. Efficacy and tolerability of phototherapy with light-emitting diodes for sensitive skin: A pilot study. *Front Med (Lausanne)*. 2020;7:35. doi:10.3389/FMED.2020.00035
- Choi M, Kim JE, Cho KH, et al. In vivo and in vitro analysis of low level light therapy: A useful therapeutic approach for sensitive skin. *Lasers Med Sci*. 2013;28(6):1573-1579. doi:10.1007/S10103-013-1281-X
- Jin T, Pan L, Zhao Y, et al. Treatment of sensitive skin by short-wave radiofrequency combined with intense pulsed light. *J Cosmet Dermatol*. Epub ahead of print; Sep 6, 2022. doi:10.1111/JOC.D.15322
- Ye C, Zhang Y, Su Z, et al. hMSC exosomes as a novel treatment for female sensitive skin: An in vivo study. *Front Bioeng Biotechnol*. 2022;10. doi:10.3389/FBIOE.2022.1053679
- García-Millán C, Pino A, Rodrigues R, et al. An autologous topical serum derived from platelet-rich plasma therapy for the management of sensitive skin alterations: A case series report. *Clin Cosmet Investig Dermatol*. 2022;15:2077-2086. doi:10.2147/CCID.S379323
- Ferreira MS, Sousa Lobo JM, Almeida IF. Sensitive skin: Active ingredients on the spotlight. *Int J Cosmet Sci*. 2022;44(1):56-73. doi:10.1111/ICS.12754
- Coderch L, López O, de La Maza A, et al. Ceramides and skin function. *Am J Clin Dermatol*. 2003;4(2):107-129. doi:10.2165/00128071-200304020-00004
- Ma Y, Cui L, Tian Y, et al. Lipidomics analysis of facial lipid biomarkers in females with self-perceived skin sensitivity. *Health Sci Rep*. 2022;5(3). doi:10.1002/HSR2.632
- Cho HJ, Chung BY, Lee HB, et al. Quantitative study of stratum corneum ceramides contents in patients with sensitive skin. *J Dermatol*. 2012;39(3):295-300. doi:10.1111/J.1346-8138.2011.01406.X
- Yashiki K, Ohto N, Kawashima Y, et al. The effect of dipotassium glycyrrhiza on sensitive skin care. *Journal of Society of Cosmetic Chemists of Japan*. 2017;50(4):334-339. doi:10.5107/SCCJ.50.334
- Schoelermann AM, Jung KA, Buck B, et al. Comparison of skin calming effects of cosmetic products containing 4-t-butylcyclohexanol or acetyl dipeptide-1 cetyl ester on capsaicin-induced facial stinging in volunteers with sensitive skin. *J Eur Acad Dermatol Venereol*. 2016;30 Suppl 1:18-20. doi:10.1111/JDV.13530
- Jovanovic Z, Angabini N, Ehlen S, et al. Efficacy and tolerability of a cosmetic skin care product with Trans-4-t-butylcyclohexanol and Licochalcone A in subjects with sensitive skin prone to redness and rosacea. *J Drugs Dermatol*. 2017;16(6):605-610.
- Sulzberger M, Worthmann AC, Holtzmann U, et al. Effective treatment for sensitive skin: 4-t-butylcyclohexanol and licochalcone A. *J Eur Acad Dermatol Venereol*. 2016;30:9-17. doi:10.1111/jdv.13529
- Draeos ZD, Gunt H, Zeichner J, et al. Clinical evaluation of a nature-based bakuchiol anti-aging moisturizer for sensitive skin. *J Drugs Dermatol*. 2020;19(12):1181-1183. doi:10.36849/JDD.2020.5522
- Guéniche A, Bastien P, Ovigne JM, et al. Bifidobacterium longum lysate, a new ingredient for reactive skin. *Exp Dermatol*. 2010;19(8). doi:10.1111/J.1600-0625.2009.00932.X
- Kern C, Gombert C, Roso A, et al. Effect of the supplementation of virgin coriander seed oil on reducing reactivity in healthy women with sensitive skin: a randomized double-blind placebo-controlled pilot clinical study. *Food Nutr Res*. 2022;66. doi:10.29219/FNR.V66.7730
- Neukam K, de Spirt S, Stahl W, et al. Supplementation of flaxseed oil diminishes skin sensitivity and improves skin barrier function and condition. *Skin Pharmacol Physiol*. 2011;24(2):67-74. doi:10.1159/000321442
- de Campos Dieamant G, Velazquez Pereda MDC, Eberlin S, et al. Neuroimmunomodulatory compound for sensitive skin care: in vitro and clinical assessment. *J Cosmet Dermatol*. 2008;7(2):112-119. doi:10.1111/J.1473-2165.2008.00373.X
- Hettwer S, Bänziger S, Suter B, et al. Grifolin derivatives from *Albatrellus ovinus* as TRPV1 receptor blockers for cosmetic applications. *Int J Cosmet Sci*. 2017;39(4):379-385. doi:10.1111/ICS.12385
- Seité S, Benec'h F, Berdah S, et al. Management of rosacea-prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water as monotherapy or adjunctive therapy. *J Drugs Dermatol*. 2013;12(8):920-924. Accessed November 15, 2022. <https://europepmc.org/article/med/23986166>

AUTHOR CORRESPONDENCE

Adam Friedman MD FAAD

E-mail: ajfriedman@mfa.gwu.edu